Medical devices, healthcare technology and the business of care
PMA approval · P240012

AeroPace System

Lungpacer Medical USA, Inc. · Decision date Dec 4, 2024

FDA DECISIONP240012

What did the FDA approve?

FDA records P240012 as an original PMA application. The recorded decision is approval, dated Dec 4, 2024.

FDA approval order statement

Approval for AeroPace System. The AeroPace System is indicated to improve weaning success increase weaning, reduce ventilator days, and reduce reintubation - in patients ages 18 years or older on mechanical ventilation >= 96 hours and who have not weaned.
Regulatory pathway
Original PMA
Clinical specialty
Anesthesiology
Decision date
Dec 4, 2024

FDA source record

Regulatory record facts

Identifier
P240012
Regulatory pathway
Premarket approval application
Product code
SDL
Decision code
APPR
Decision date
Dec 4, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transvenous temporary phrenic nerve stimulator.

Product code
SDL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240012 received

    Application receipt date recorded by FDA.

  2. P240012 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P240012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240012

Product / regulatory recordCompanyPathwayDecision dateSource
AeroPace SystemP240012/S008
Lungpacer Medical USA, Inc.PMA supplementSep 25, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lungpacer Medical USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
260 Sierra Dr., Suite 116, Exton, PA, 19341

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records